Skip to content
Menu

Disc Medicine, Inc. IRON

Full chart Compare
Set alert

Price alert · IRON

All alert types
76.11 USD -1.87 (-2.40%)

Regular-session close

76.11 0.00 0.00%

After hours · Nov 19, 4:26 PM ET

75.98 Day range 78.90
40.00 52-week range 99.50
YTD
-4.16%
1 year
-16.12%

5D -5.69 (-6.87%)

7577.508082.50FriMonTueWedThu77.10
Market cap
3.47B
EPS (ttm)
-6.34
Shares out
45.54M
Forward P/E
-12.32
YTD return
-4.16%
1-year return
-16.12%
50-day average
71.57
200-day average
70.92
Enterprise value
2.93B
Price / book
4.86
Volume
646.41K
Avg volume
943.68K
Open
78.44
Previous close
77.98
Day's range
75.98 – 78.90
52-week range
40.00 – 99.50
Beta
2.01
Analysts
Strong Buy
Price target
127.69 (+67.8%)
Earnings date
Feb 25, 2027

Key statistics

Free cash flow
-112.66M
Total cash
682.82M
Total debt
61.09M
Return on equity
-41.29%
Short % of float
17.13%

Fundamental scorecard

3 of 25 checks passed on IRON’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IRON Revenue — quarterly 0
IRON Net income — quarterly -59.53M
IRON EPS — quarterly -1.53

Earnings

IRON recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-1.49———
Nov 5, 2026Sep 30, 2026-1.63-1.53+0.10+6.13%
Jul 30, 2026Jun 30, 2026-1.71-1.54+0.17+9.94%
May 5, 2026Mar 31, 2026-1.55-1.65-0.10-6.45%
Feb 26, 2026Dec 31, 2025-1.69-1.62+0.07+4.14%
Nov 6, 2025Sep 30, 2025-1.48-1.77-0.29-19.59%

Upgrades / downgrades

IRON analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026Guggenheiminit—Buy
Nov 6, 2026HC Wainwright & Co.mainBuyBuy
Oct 20, 2026Morgan StanleymainOverweightOverweight
Oct 20, 2026Truist SecuritiesmainBuyBuy
Oct 20, 2026Wells FargomainOverweightOverweight
Oct 20, 2026WedbushmainOutperformOutperform

About Disc Medicine, Inc.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on IRON — it syncs with the Stock Master app.

Insider holders

IRON insider holders
InsiderRelationLatest transactionDateShares held
AI DMI ,L.L.C.Beneficial Owner of more than 10% of a Class of SecuritySaleOct 21, 20250
ASHIYA MONADirectorSaleMar 23, 20250
BITTERMAN KEVIN JDirectorSaleOct 20, 20260
FRANCHI JEAN MChief Financial OfficerSaleApr 13, 202664,333
KHARA RAHULOfficerConversion of Exercise of derivative securityAug 5, 202652,324
ORBIMED ADVISORS, L.L.C.UnknownSaleMar 23, 20250

Institution ownership

IRON institution ownership
Holder% heldSharesValueReported
FMR, LLC10.55%4,803,145365.57MSep 29, 2026
Blackrock Inc.5.56%2,532,863192.78MSep 29, 2026
RA Capital Management, L.P.5.38%2,450,221186.49MSep 29, 2026
JPMORGAN CHASE & CO3.98%1,812,170137.92MSep 29, 2026
Wellington Management Group, LLP3.86%1,756,490133.69MSep 29, 2026
Price (T.Rowe) Associates Inc3.63%1,655,238125.98MSep 29, 2026

Fund ownership

IRON fund ownership
Holder% heldSharesValueReported
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 4.96%2,258,062171.86MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.13%970,66173.88MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.61%732,56955.76MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.58%719,75554.78MSep 29, 2026
JPMorgan Trust II-JPMorgan Mid Cap Growth Fund1.42%647,79449.30MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.1.24%566,76043.14MJun 29, 2026